Kadmon Holdings LLC (NASDAQ:KDMN) shares traded down 4.1% during mid-day trading on Thursday . The company traded as low as $9.27 and last traded at $9.35, with a volume of 148,610 shares traded. The stock had previously closed at $9.75.

A number of research analysts recently issued reports on the company. JMP Securities assumed coverage on Kadmon Holdings in a report on Monday, August 22nd. They set an “outperform” rating and a $16.00 price objective for the company. WBB Securities assumed coverage on Kadmon Holdings in a report on Monday, August 1st. They set a “sell” rating and a $7.50 price objective for the company. Jefferies Group assumed coverage on Kadmon Holdings in a report on Monday, August 22nd. They set a “buy” rating and a $12.00 price objective for the company. HC Wainwright assumed coverage on Kadmon Holdings in a report on Monday, August 22nd. They set a “buy” rating and a $25.00 price objective for the company. Finally, Citigroup Inc. assumed coverage on Kadmon Holdings in a report on Monday, August 22nd. They set a “neutral” rating and a $12.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $14.50.

The company’s market capitalization is $78.64 million. The firm’s 50-day moving average price is $9.93 and its 200-day moving average price is $9.93.

In related news, major shareholder Daniel S. Loeb bought 66,828 shares of the business’s stock in a transaction on Friday, August 5th. The shares were purchased at an average cost of $9.94 per share, with a total value of $664,270.32. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, major shareholder Daniel S. Loeb bought 6,010 shares of the business’s stock in a transaction on Monday, August 15th. The shares were bought at an average cost of $9.95 per share, for a total transaction of $59,799.50. The disclosure for this purchase can be found here.

Kadmon Holdings, LLC is a biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of unmet medical need. The Company is developing product candidates within autoimmune and fibrotic diseases, oncology and genetic diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.